Full-Time

Director – Global Commercial

Sonrotoclax

Posted on 12/13/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$187.1k - $247.1k/yr

+ Annual Bonus + Incentive Compensation Plan + Equity Awards + Employee Stock Purchase Plan

Remote in USA

Hybrid

Approximately 20% travel, including international travel.

Category
Growth & Marketing (1)
Requirements
  • BA/BS degree is required.
  • MA/MS degree or MBA is preferred.
  • PhD or PharmD degree is preferred.
  • 10+ years of pharmaceutical marketing and/or healthcare-related commercial experience.
  • Experience in global or regional markets (US, EU, or China) and launch environments is strongly preferred.
  • Background in hematology or highly competitive therapeutic categories is preferred.
  • Demonstrated ability to lead without authority and influence cross-functional teams.
  • Strong experience with omnichannel marketing and data-driven campaign execution.
  • Prior success in competitive preparedness and market-shaping initiatives.
  • Skilled in integrating insights from customer research, analytics, and field feedback.
  • Excellent communication skills.
  • Travel approximately 20%, including international travel.
  • PC, including MS Office Suite, MS Teams.
Responsibilities
  • Develop and lead global professional promotional strategy for Sonrotoclax, in alignment with brand positioning and cross-functional objectives.
  • Serve as global omnichannel lead, shaping the vision and pull-through of multichannel customer engagement tactics.
  • Collaborate with local markets to align on core campaign content, digital execution, and promotional pull-through.
  • Lead global cross-functional competitive readiness workstreams to identify, evaluate, and prepare for key competitive events and market dynamics.
  • Partner with Medical Affairs, Regulatory, Access, and marketing teams to craft responsive and proactive competitive messaging and materials.
  • Collaborate with global and local congress leads to ensure consistent, compliant, and impactful representation of Sonrotoclax at key conferences.
  • Lead and manage global market research efforts to inform commercial strategy, positioning, messaging, and decision-making across key indications.
  • Act as a liaison for insight generation, consolidating feedback across global teams and tracking shifts in the market landscape.
  • Collaborate closely with other GCSO team members focused on launch strategy, operations, and communications.
  • Partner with local marketing teams to support implementation of global promotional and competitive readiness strategies.
  • This position does not have direct reports, but will require strong leadership of agency partners and cross-functional teams.
Desired Qualifications
  • MA/MS with 7+ years of marketing experience.
  • MBA with 7+ years of marketing experience.
  • PhD/PharmD with 5+ years of marketing experience.
  • Experience in hematology or highly competitive therapeutic categories is preferred.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE